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Thrombotic thrombocytopenia purpura (TTP) caused by a deﬁciency in ADAMTS-13 activity is considered to involve a subset of
thrombotic microangiopathy (TMA). Although concept of TTP is included under the umbrella of TMA, discrimination of TTP
from TMA is occasionally diﬃcult in an autoimmune disorder. Herein, we report a case with TTP associated with systemic lupus
erythematosus (SLE). In this case, it was diﬃcult to discriminate TTP from TMA and the measurement of ADAMTS-13 activity
was useful for obtaining an accurate diagnosis. SLE patients having thrombocytopenia in complication with anemia should be
considered a monitoring of ADAMTS-13 activity even though the patients lacked symptoms of TTP related to the microvascular
coagulation.
1.Introduction
Thrombotic thrombocytopenic purpura (TTP) is a life-
threatening syndrome ﬁrst described by Moschocowitz in
1924 [1]. TTP is clinically characterized by ﬁve typi-
cal syndromes: thrombocytopenia with platelet consump-
tion, hemolytic anemia characterized by schistocytes, renal
impairment, neurological abnormalities, and fever. The
classic pentad described above is observed in as few as
40% of TTP patients [2], and the clinical course of the
syndrome is usually rapid, therefore, an accurate diagnosis
and immediate treatment including plasma exchange is
necessary [3]. Von Wiilebrand factor-(vWF)-speciﬁc met-
alloprotease, a disintegrin-like and metalloprotease with
thrombospondintype1motif-13(ADAMTS-13)isknownto
play an important role in the pathogenesis of TTP [4–6]. A
severe deﬁciency of ADAMTS-13 activity prevents the phys-
iological processing of large vWF multimers which can lead
to a strong platelet aggregation, and leads to the formation
of microthrombosis in terminal arterioles and capillaries.
Besides TTP, microthrombosis without a deﬁciency in
ADAMTS-13 activity can also be associated with other
diseases such as hemolytic uremic syndrome (HUS), various
autoimmune diseases, cytotoxic drugs, human immunode-
ﬁciency virus (HIV), malignancies, disseminating intravas-
cular coagulopathy (DIC), and pre-eclampsia [7]. Recently,
these pathological conditions characterized by microthrom-
bosis including TTP, have been classiﬁed as thrombotic
microangiopathies (TMA). In autoimmune disorders, TMA
occasionally occurs in systemic lupus erythematosus (SLE),
antiphospholipid antibody syndrome (APS) [8, 9], and in
many rare autoimmune disorders [7]. Rigorous classiﬁcation
of TMA is important to decide on the appropriate therapy.
In particular, the combination of TTP and SLE has been
reported to show a worse prognosis than SLE or idiopathic
TTP alone [10], therefore, an accurate diagnosis and an
immediate treatment are required.
Taken together, we recently encountered a case of SLE
associated with TTP. This case indicated the diagnostic2 Autoimmune Diseases
Table 1: Laboratory test results on admission.
Blood test
WBC 5100/mm3 CH50 21U/mL
Neutro 45.5% C3 81mg/dL
Lymph 45.5% C4 8mg/dL
Mono 6.0% IgG 1525mg/dL
Eo 0% IgA 190mg/dL
Baso 0% IgM 40mg/dL
RBC 219/mm3 ANA ×320
Reticuro 7.2% Speckled ×320
Hb 6.4g/dL Anti-DNA
antibody (RIA) 27IU/mL
Hct 18.0% Anti-SS-A
antibody 1160U/mL
Plt 0.4/mm3 Anti-SS-B
antibody (−)
PT-INR 1.11 Anti-Topo-1
antibody (−)
ATPP
29.1sec
(contro;
30.3sec)
Anti-RNP
antibody 184U/mL
FDP 17.4μg/dL Anti-Sm
antibody (−)
D-D 8.78μg/dL MPO-ANCA (−)
ESR 66mm/h Anti cardiolipin
antibody (IgG) 13U/mL
TP 6.9g/dL Anti-CLβ2GP1
antibody (−)
ALB 3.7g/dL LAC (−)
BUN 10mg/dL Anti platlet
antibody (−)
Cr 0.54mg/dL PA-IgG 2150ng/107 cell
UA 3.0mg/dL IC-C1q 3.3μg/mL
Na 136mmol/L Direct Coombs
test (−)
K 3.9mmol/L Indirect Coobms
test (−)
CL 102mmol/L CMV IgG (+)
T-Bil 2.9 mg/dL CMV IgM (−)
D-Bil 0.9mg/dL CMV Ag (−)
AST 61IU/L EBV EBNA (−)
ALT 35IU/L EBV-VCAIgG (+)
LDH 915IU/L EBV Ag (+)
CK 77IU/L EBV-VCAIgM (−)
CRP <0.3mg/dL HBs Ag (−)
Urianalysis
Glu (−)
Protein (−)
RBC (−)
WBC (−)
abnormal
cyst (−)
diﬃculty of TTP associated with autoimmune diseases such
as SLE and the diagnostic eﬃcacy of immediate monitoring
of ADAMTS-13 activity for distinguishing TTP from other
TMA.
2.CaseReport
A15-year-oldfemalewasadmittedtoourhospitalbecauseof
thrombocytopenia with hemolytic anemia. She had noticed
small purpura on her arms and her legs during 2 weeks
before the admission. At the same time, she started having
headaches,polyarthritis,andshortnessofbreathonexertion.
These symptoms progressively deteriorated, thus prompting
herhospitalvisit.Onherphysicalexamination,bodytemper-
aturewas38.2◦C.Herconsciousnesswasalert.Smallpurpura
were scattered over her entire arms and legs. A malar rash
was also recognized on her face. Broad spectrum antibiotic
(doripenem hydrate, 1.5g/day) was involved in the initial
therapy because severe bacterial infection was suspected in
the situation with undetermined diagnosis on the admission.
However, bacterial cultures from her blood, urine, sputum,
and throat swab revealed no signs of any bacterial infections
and we subsequently excluded bacterial infection from the
diagnosis. Titers of antibodies against various kinds of
virus such as cytomegalovirus, Epstein-Barr virus, and par-
vovirus B19 were also negative. Laboratory ﬁndings revealed
thrombocytopenia with hemolytic anemia. A summary of
the laboratory tests on admission is shown in Table 1.
The serum hemoglobin level was low at 6.4g/dL (normal
range; 12.0–16.0g/dL), her platelet count was also low at
4000/μL (normal range; 15.0–35.0 × 104/μL). The number
of white blood cells was within normal range. Although
the serum levels of ﬁbrinogen degradation products (FDP)
and D-dimers were elevated to 17.4μg/dL (normal range;
less than 5.0μg/dL) and 8.78μg/dL (normal range; less than
2.0μg/dL), respectively, suggesting DIC, the other parame-
tersrelatedtoDIC,suchastheserumlevelofﬁbrinogen,pro-
thrombin time (PT), and activated partial thromboplastin
time (aPTT) were normal. The serum level of lactate dehy-
d r o g e n a s e( L D H )w a se l e v a t e dt o9 1 5I U / L( n o r m a lr a n g e ;
119–219IU/L), and that of total bilirubin level was also
elevated at 2.9mg/dL (normal range; 0.2–1.3mg/dL) with
dominant elevation of indirect bilirubin. The blood urea
nitrogen(BUN)andcreatininelevelswerewithinthenormal
range and urinalysis did not show any abnormal ﬁndings.
Although her serum haptoglobin levels were decreased at
less than 10mg/dL (normal range; >43–180) thus suggesting
hemolytic anemia, both the direct and indirect Coombs tests
were negative. The patient’s bone marrow cells obtained
by aspiration revealed normal diﬀerentiation, however, a
peripheral blood smear test clearly showed schistocytes in
the RBC. Her antinuclear antibody (ANA) test was positive,
and she also had anti-DNA antibodies, anti-SS-A antibodies,
anti-RNP antibodies, and anticardiolipin antibodies. Her
serum complement levels were decreased (CH50; 21U/mL,
C3; 81mg/dL, and C4; 8mg/dL, normal range; CH50 32–
49U/mL, C3 65–135mg/dL, C4 13–35mg/dL, resp.) and
increased immune complex formation was observed (ICc1q
3.3μg/mL, normal range; 0–3.0μg/mL). She thus fulﬁlled
the criteria for systemic lupus erythematosus (SLE) basedAutoimmune Diseases 3
mPSL 1000mg/day (day 1 ∼ 3)
PSL 50mg/day 45mg/day 40mg/day 35mg/day
Fever
Purpura
Plasma exchange (day 2 ∼ 6)
Heparin 10000u/day Aspirin 100mg/day
Doripenem hydrate 1.5g/day (day1 ∼ 5)
Day after admission 1 5 10 15 20 25 30 35 40
Hemoglobin (g/dL) 5.6 5.1 7.5 8.6 10.1 11.2 12.5 13.6 13.5
Schistocytosis (++) (+) (+−)( −)( −)( −)( −)( −)( −)
Platelet (×104/µL) 0.4 4.4 15.5 11.2 28.7 34.6 30.6 29.7 25.8
CH50 (U/mL) 21 30 49 52
4 1 7 2 ) L m / U I ( b A A N D - i t n A
8 6 1 0 6 0 ) % ( y t i v i t c a 3 1 S T M A D A
Figure 1: The clinical course in the present case. The patient was treated with intravenous administration with methylprednisolone
(1000mg/day for 3 days on the admission) followed by oral administration with prednisolone (50mg/day). Daily plasma exchange and
anticoagulant therapy was added on the second day. Plasma exchange was performed for 5 consecutive days and stopped at the sixth day of
the admission. Subsequently, peripheral schistocytes diminished, her hemoglobin level and platelet count were improved, the complement
level increased, the titer of anti-DNA antibody decreased, and the ADAMTS-13 activity increased. mPSL: methylprednisolone, and PSL:
prednisolone.
on these laboratory ﬁndings (positive for ANA, anti-DNA
antibody, anti-cardiolipin antibody, and thrombocytopenia)
and her symptoms, such as malar rash and polyarthritis. At
this moment, her SLE disease activity score (SLEDAI) was
13,thusindicatinghighdiseaseactivity.Onadmission,TMA,
seronegative autoimmune hemolytic anemia with thrombo-
cytopenia (EVANS syndrome), CAPS, and DIC were consid-
ered as possible candidates for her thrombocytopenia with
hemolytic anemia. We provisionally diagnosed her illness as
TMA with complicated autoimmune disorder because of a
negative Coombs test, hemolytic anemia with schistocytes
and thrombocytopenia, and immunosuppressive therapies,
which consisted of intravenous cyclophosphamide adminis-
tration (500mg/body) and intravenous methylprednisolone
(1000mg/body, 3 days) administration followed by oral
administration of prednisolone (50mg/day), were initially
introduced. However, the immunosuppressive therapy did
not ameliorate her illness, therefore, we suspected TTP. As
expected, additional laboratory tests showed that her serum
ADAMTS-13 activity was obviously suppressed to an unde-
tectable level. Although she did not have typical symptoms
of TTP such as renal dysfunction and abnormalities of the
central nervous system, we diagnosed her illness as TTP.
Plasma exchange therapy was immediately added to her
treatment. The therapy was continued for 5 consecutive
days, then, her symptoms and the abnormal ﬁndings of
laboratory tests completely disappeared. The clinical course
of the patient is summarized and illustrated in Figure 1.T h e
serum level of ADAMTS-13 activity was restored from an
undetectable level to 60% of normal on day 17, and 168%
on day 47, concomitant with the disease amelioration. She
was discharged without any symptoms.
3. Discussion
We herein reported a case of SLE associated with TTP.
Because the patient lacked variable signs/symptoms of organ
ischemia related to thrombosis in capillary arteries, it was
diﬃcult to determine the diagnosis of TTP at presentation.
She was diagnosed with SLE based on her physical and
laboratory ﬁndings (such as a malar rash, polyarthralgia,
increased levels of several autoantibodies, and decreased
serum complement concentrations). Decreased levels of
ADAMTS-13indicatedthatshehadbeensuﬀeringfromTTP
as well, and that her TTP contributed to the development of
her thrombocytopenia and hemolytic anemia. TTP is clas-
siﬁed as congenital and acquired type. Whereas congenital
ADAMTS-13 deﬁciency is rare, loss of ADAMTS-13 activity
is observed more frequently in acquired TTP. The ADAMTS-
13 deﬁciency can be caused by an autoantibody and various
other factors having an inhibitory eﬀect on ADAMTS-13
activity [4].
Although the loss of ADAMTS-13 activity is the most
important factor for diagnosis of TTP, it has been reported
a few diseases condition resulted in ADAMTS-13 deﬁciency
other than TTP. Nguyen and coworkers has reported that
patients with severe sepsis revealed reduced ADAMTS-
13 activity and the deﬁciency correlated with severity of
thrombocytopenia and plasma level of interleukin-6 (IL-6)
[11]. Indeed, mild- to-moderate ADAMTS-13 deﬁciency has
been detected in systemic inﬂammation [12]. These reports4 Autoimmune Diseases
Table 2: Diﬀerential diagnosis of hemolytic anemia with thrombocytopenia. The diseases possibly resembling TTP are summarized in
Table 1. TTP: thrombotic thrombocytopenic purpura, HUS: hemolytic-uremic syndrome, CAPS: catastrophic anti-phopholipid antibody
syndrome, DIC: disseminating intravascular coagulopathy.
TTP HUS EVANS syndrome CAPS DIC
Tthrombocytopenia (+) (+) (+) (+) (+)
Hemolytic anemia (+) (+) (+) (+−)( + −)
Sschistocytes (++) (+) (+−)( + −)( + −)
Clinical ﬁndings
Mental disorder Diarrhea Autoimmue reaction Multiple organ infarction Underlying disease
Renal dysfunction Renal dysfunction
Fever up
Speciﬁc laboratory
ﬁndings
Suppression of
ADAMTS-13 activity
Positive for
Shiga-toxin
Positive for Coombs
test
Antiphospholipid
antibodies
Elevation of FDP
Ttreatment
Plasma exchange Hydration Steroids Anti-coagulant therapy Anti-coagulant
therapy
Steroids Plasma exchange Immunosuppression
therapy (IVCY)
Steroids Treatment for
underlying disease
1mmunosuppression
therapy(IVCY)
Iimmunosuppression
therapy (IVCY)
Anti-coagulant
therapy Plasma exchange
suggest that inﬂammatory cytokines contribute to the deﬁ-
ciency of ADAMTS-13. Patients with SLE have been known
to have an elevated serum level of cytokines due to aberrant
activation of autoreactive lymphocytes. In the present case,
some kind of cytokines may play an important role for
deﬁciencyofADAMTS-13incoordinationwithaproduction
of inhibitory autoantibody against ADAMTS-13. Moreover,
Lattuada et al. has reported that pregnant woman with
HELLP syndrome (hemolytic anemia, elevated liver enzyme,
and low platelets) had lower plasma levels of ADAMTS-13
activity [13]. Although some of clinical presentation TTP are
shared by patients with severe sepsis and HELLP syndrome,
the eﬀective treatments diﬀer in each diseases even though
the deﬁciency of ADAMT-13 are observed in common with
these diseases. No matter ADAMTS-13 deﬁciency observed,
we should still take a possibility of other diseases condition
into account in addition to TTP.
Althoughplasmaexchangeisthemosteﬀectivetreatment
of TTP, it also can be used in other clinical manifestations
related to SLE. Pugnoux et al. have reported that plasma
exchange has beneﬁcial eﬀects for SLE-related diseases
such as neurolupus, alveolar hemorrhage, and severe lupus
nephritis [14]. Furthermore, Cerdas-Quesada have reported
that refractory AIHA was successfully treated with plasma
exchange [15]. The clinical manifestations of these diseases
are shared with those of TTP. The rationale to use plasma
exchange for the disease state is a removal of pathological
autoantibodies, cytokines, and unknown harmful factors.
In addition to TTP, the plasma exchange may be used for
other complications of SLE as a supportive treatment until
immunosuppressive therapy become eﬀective. If immediate
curative eﬀects are required, plasma exchange may be an
important strategy for certain SLE-rerated diseases even
though TTP does not exist.
Similar to our case, autoimmune disorder occasionally
makes it diﬃcult to diagnose TTP, especially in the patients
lacking typical clinical signs/symptoms of the disease. More-
over, it may be diﬃcult to distinguish TTP from the other
types of TMA. The possible diﬀerential diagnosis and the
clinical diﬀerences among representative TMA including
TTP are summarized in Table 1. HUS is characterized as
renal diseases and usually associated with bacterial colitis
(Escherichia coli O157 and Shigella-toxin-producing strain).
HUS can be distinguished from TTP by diarrhea (D+HUS).
Our patient had not shown any digestive symptoms;
however, diarrhea negative (D-HUS) cases of HUS have
been reported. EVANS syndrome, which is characterized by
autoimmune hemolytic anemia (AIHA) with autoimmune
thrombocytopenia, is also considered as one of important
diﬀerentialdiagnosisfromTTP.ThedetectionofRBCbound
immunoglobulinGandcomplementbythedirectantiglobu-
lintest(DAT;Coombstest)isusefulinthediagnosisofAIHA
[16]. The Coombs test in our patient was negative, although
a small number of patients with AIHA have been reported
to show a negative DAT [17], probably because of the lower
aﬃn i t yo fI g Gt oR B C[ 18]. Therefore, the lack of these
autoantibodies cannot conclusively exclude AIHA and/or
EVANS syndrome. Catastrophic antiphospholipid syndrome
(CAPS) which is an accelerated from APS [19]i sar e l a t i v e l y
new entity and thought to be a rare disease, although the
exact thrombogenic mechanisms of CAPS remain unclear.
The treatment of CAPS is not currently standardized and the
prognosis is poor with death occurring in 50% of patients
[20]. The diagnosis of TTP in patients with SLE could
be diﬃcult in SLE cases of positive for antiphospholipid
antibody. In fact, laboratory ﬁndings in our patient revealed
positivity for aCL, therefore, we also had to take CAPS into
account as the possible diagnosis. However, the diagnosis ofAutoimmune Diseases 5
CAPS was not unlikely in the present case because of low
titer of aCL. Regarding DIC, our patient was thought to have
SLE with an elevation in the serum levels of FDP and D-
dimer, suggesting DIC. Although the pathogenesis of DIC
in SLE patients is still not fully understood, vasculitis has
been considered to be involved in the pathogenesis of DIC in
patients with SLE [21]. Immune complexes (ICs) activated
by complements may injure the vascular endothelial cells,
resulting in the release of tissue thromboplastin [21, 22].
Therefore, discrimination of TTP from a certain case with
SLE may be diﬃcult in such cases as the present case. In
these situations, tests of the ADAMTS-13 activity seem to
be the most useful tool for the diagnosis in TTP. Fujimura
and Matsumoto categorized TTP using plasma levels of
ADAMTS13 activity (<3%; severe, 3–25%; moderate, 25–
50%; mild) for the purpose of distinguishing TTP from
TMA. They also reported that the levels of ADAMTS-13
activity are lower in idiopathic TTP than in secondary
TTP [23]. Generally, patients with autoimmune diseases
tended to a have mild-to-moderate deﬁciency in ADAMTS-
13 activity. In addition, Coppo et al. reported that patients
with severe ADAMTS-13 deﬁciency in adult idiopathic TMA
are characterized by various autoimmune manifestations,
a lower platelet count, and mild renal involvement [24].
Although our patient was diagnosed as SLE, she had a
severedeﬁciencyinherADAMTS-13level(<0.3),andsteroid
treatment was not suﬃciently eﬀective for her symptoms.
Hermainsymptomswerethoughttohavebeencausedbyher
TTP, and plasma exchange treatment were performed, and
thereafter her clinical and laboratory data were dramatically
improved.
Patient with congenital TTP, which results from a
congenital deﬁciency in ADAMTS-13, may beneﬁt from
plasma infusion. Those with acquired TTP may also beneﬁt
from plasma exchange by the removal of the vWF-cleaving
protease inhibitors, thereby restoring the ADAMTS-13 level.
There is no proven beneﬁt for plasma exchange in TMA
(except TTP) associated with autoimmune-disorders. In
such case, immunosuppressive therapy or B-cells depletion
therapy by biologics may be a better choice than plasma
exchange. Plasma exchange therapy has been widely used
and is regarded as the for best treatment for TTP, however,
the eﬃcacy of plasma exchange has not been established in
other type of TMA, and other therapeutic strategies may be a
better choice, such as immunosuppressive agents, antibiotics
(in cases of infection associated-TMA), and anticancer drugs
(in cases of malignancy associated-TMA).
TTP has been sporadically reported in patients with SLE
[25]. SLE and TTP share similar clinical symptom, therefore,
complication of TTP in patients with SLE may be missed
if careful and extensive studies are not performed. Plasma
exchange is currently considered the most eﬀective treat-
ment for TTP, whereas immunosuppressive drugs (including
steroids) are considered to be the most eﬀective for SLE.
TTP is a rare but life-threatening complication of SLE. Our
present case suggested that prompt diagnosis of TTP by
monitoring of the ADMATS-13 level if there is a suspicion
of TTP, and the consequent intensive treatment including
plasmaexchangewithadequateimmunosuppressivetherapy,
are required to rescue patients from these life-threatening
disorders.
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